Hepatitis B
|
0.400 |
Biomarker
|
disease |
BEFREE |
Conclusion: These findings highlight a host gene, UBE2L3, contributing to the susceptibility to persistent HBV infection; UBE2L3 may be involved in IFN-mediated viral suppression and serve as a potential target in the prevention and treatment of HBV infection.
|
30614547 |
2019 |
Hepatitis B
|
0.400 |
Biomarker
|
disease |
BEFREE |
In summary, our study suggests that HBV precore protein, specifically the p22 form, impedes JAK-STAT signaling to help the virus evade the host innate immune response and, thus, causes resistance to IFN therapy.<b>IMPORTANCE</b> Chronic hepatitis B virus (HBV) infection continues to be a major global health concern, and patients who fail to mount an efficient immune response to clear the virus will develop a life-long chronic infection that can progress to chronic active hepatitis, cirrhosis, and primary hepatocellular carcinoma.
|
31019054 |
2019 |
Hepatitis B
|
0.400 |
Biomarker
|
disease |
BEFREE |
Identifying the key negative factors and elucidating the regulating mechanism are essential for improving anti-HBV (hepatitis B virus) efficacy of IFNα.
|
30723923 |
2019 |
Hepatitis B
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Inhibition of miR-3613-3p decreased relative expressions of IFN-α and IFN-β, HBV DNA copies, and increased the hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) levels, whereas miR-3613-3p overexpression reversed these changes in vitro and in vivo.
|
31201869 |
2019 |
Hepatitis B
|
0.400 |
Biomarker
|
disease |
BEFREE |
In conclusion, the measurement of HBV RNA prior to PEG-IFN-based therapy could identify patients with high probability of MVR.
|
31446638 |
2019 |
Hepatitis B
|
0.400 |
Biomarker
|
disease |
BEFREE |
In this study, 74 patients with chronic HBV infection who had virological responses to 180 μg/week Peg-IFNα-2a treatment were included; 38 (20 and 18 HBeAg positive and negative, respectively) of these patients were treated with 245 mg/day TDF, and 36 (20 and 16 HBeAg positive and negative, respectively) were treated with 0.5 mg/day ETV upon relapse after initial treatment discontinuation.
|
30963812 |
2019 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Mice incapable of downregulating the IFN receptor and Ch25h were resistant to TEV uptake, TEV-induced pre-metastatic niche, and melanoma lung metastases; however, ablation of Ch25h reversed these phenotypes.
|
30645975 |
2019 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
A unique case of NMOSD caused by IFN-α therapy in malignant melanoma is presented.
|
31030016 |
2019 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Multiple antigen-engineered DC vaccines with or without IFNα to promote antitumor immunity in melanoma.
|
31014399 |
2019 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Treating with anti-HN neutralizing mAb induced significant decline in the cytotoxicity of IFN R<sup>-/-</sup> NK cells toward Hepa1-6 cell line (P < 0.05).
|
31120191 |
2019 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Compared with IFN-only regimen, no significant increase in HCC risk was found for use of DAA-only (HR, 1.53; 95% CI, 0.73-3.23), DAA + IFN (HR, 1.02; 95% CI, 0.51-2.06), or any-DAA (HR, 1.04; 95% CI, 0.65-1.65).
|
31451519 |
2019 |
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
PD-L1 positive HCC was observed in 6 cases of the IFN group and 4 cases of the DAA group.
|
31423211 |
2019 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We further found that RIP3 knockdown results in an increase of MDSCs and a decrease of interferon gamma-positive (IFN-γ<sup>+</sup> ) cluster of differentiation 8-positive (CD8<sup>+</sup> ) tumor-infiltrating lymphocytes (IFN-γ<sup>+</sup> CD8<sup>+</sup> T cells) in hepatoma tissues, thus promoting immune escape and HCC growth in immunocompetent mice.
|
31021443 |
2019 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In summary, our study suggests that HBV precore protein, specifically the p22 form, impedes JAK-STAT signaling to help the virus evade the host innate immune response and, thus, causes resistance to IFN therapy.<b>IMPORTANCE</b> Chronic hepatitis B virus (HBV) infection continues to be a major global health concern, and patients who fail to mount an efficient immune response to clear the virus will develop a life-long chronic infection that can progress to chronic active hepatitis, cirrhosis, and primary hepatocellular carcinoma.
|
31019054 |
2019 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
With CTLA-4 Nb16 stimulation, dendritic cell/hepatocellular carcinoma fusion cells (DC/HepG2-FCs) enhanced autologous CD8<sup>+</sup> T cell proliferation and production of IFN-<i>γ</i><i>in vitro</i>, thereby leading to enhanced killing of tumor cells.
|
31847937 |
2019 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Only APRI was associated with HCC recurrence; and post-IFN AFP and HCC recurrence were predictive of subsequent mortality independently.
|
30527565 |
2019 |
Hepatitis B
|
0.400 |
Biomarker
|
disease |
BEFREE |
Type I IFN (IFN-I) therapy is an important therapeutic option for HBV patients.
|
30150992 |
2018 |
Hepatitis B
|
0.400 |
Biomarker
|
disease |
BEFREE |
The use of IFNs for the treatment of viral infectious diseases on their antiviral activity may become an important therapeutic option, for example, IFN-α is well known for the successful treatment of hepatitis B and C virus infections, and interest is increasing in the antiviral efficacy of other novel IFN classes and their potential applications.
|
30537741 |
2018 |
Hepatitis B
|
0.400 |
Biomarker
|
disease |
BEFREE |
Clearance of Hepatitis B e antigen (HBeAg) was also more frequent in NASVAC group compared to Peg-IFN recipients.
|
30133478 |
2018 |
Hepatitis B
|
0.400 |
Biomarker
|
disease |
BEFREE |
In the cell-culture-based HBV infection models, the sensitivity of HBV to IFN-α in hepatocytes is determined more by the cell-intrinsic IFN response than by viral genotype, and improvement of the IFN response in HepG2-NTCP cells promotes the efficacy of IFN-α against HBV.(Hepatology 2018;67:1237-1252).
|
29059468 |
2018 |
Hepatitis B
|
0.400 |
Biomarker
|
disease |
BEFREE |
Hepatitis B surface antigen (HBsAg) decline was significantly associated with elevated CD86<sup>+</sup> pDC% (r = 0.348, P = 0.015) during PEG-IFN-α-2a treatment.
|
29791282 |
2018 |
Hepatitis B
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The largest reduction was observed in mice given NVR3-778 + peg-IFN; in all mice in this group, the serum level of HBV DNA was below the limit of quantification.
|
29079518 |
2018 |
Hepatitis B
|
0.400 |
Biomarker
|
disease |
BEFREE |
A total of 257 patients with chronic HBV, treated with PEG-IFN for 48 weeks, were identified from 13 tertiary hospitals included in the hepatitis B database of the Thai Association for the Study of the Liver (THASL).
|
28635613 |
2018 |
Hepatitis B
|
0.400 |
Biomarker
|
disease |
BEFREE |
Chronic HCV and HBV infection and IFN-based HCV therapy were not associated with DM.
|
29901821 |
2018 |
Hepatitis B
|
0.400 |
Biomarker
|
disease |
BEFREE |
Among children with hepatitis B envelope antigen-positive genotype C chronic HBV infection, we compared the efficacy of combination therapy with nucleotide analogues and IFN-α in 11 children with 12 historical cases treated with IFN monotherapy.
|
29981262 |
2018 |